Lastly, we demonstrate that ICB-resistance can effectively be overcome in combination with NeoAg vaccination in a synergistic mechanism to sustain stable CD8+ T cell responses capable of resisting the onset of terminal exhaustion and targeting both PD-L1+ and PD-L1− tumor cells. The gene discussed is CD8A; the disease is neoplasm.